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Abstract 19 
Failure of lamellar energy metabolism may contribute to the pathophysiology of equine 20 
laminitis. Tissue microdialysis has the potential to dynamically monitor lamellar energy 21 
balance over time. The objectives of this study were to develop a minimally invasive lamellar 22 
microdialysis technique and use it to measure normal lamellar energy metabolite 23 
concentrations over 24 h. Microdialysis probes were placed (through the white line) into 24 
either the lamellar dermis (LAM) (n = 6) or the sublamellar dermis (SUBLAM) (n = 6) and 25 
perfused continuously over a 24 h study period. Probes were placed in the skin dermis 26 
(SKIN) for simultaneous comparison to LAM (n = 6). Samples were collected every 2 h and 27 
analysed for glucose, lactate, pyruvate, urea and glycerol concentrations. LAM was further 28 
compared with SUBLAM by simultaneous placement and sampling in four feet from two 29 
horses over 4 h. Horses were monitored for lameness, and either clinically evaluated for 1 30 
month after probe removal (n = 4) or subjected to histological evaluation of the probe site (n 31 
= 10).  32 
 33 
There were no deleterious clinical effects of probe placement and the histological 34 
response was mild. Sample fluid recovery and metabolite concentrations were stable for 24 h. 35 
Glucose was lower (and lactate:glucose ratio higher) in LAM compared with SUBLAM and 36 
SKIN (P < 0.05). Pyruvate was lower in SUBLAM than SKIN and urea was lower in LAM 37 
than SKIN (P < 0.05). These differences suggest lower perfusion and increased glucose 38 
consumption in LAM compared with SUBLAM and SKIN. In conclusion, lamellar tissue 39 
microdialysis was well tolerated and may be useful for determining the contribution of 40 
energy failure in laminitis pathogenesis. 41 
 42 
Keywords: Horse; Laminitis; Lamellae; Bioenergetics; Urea clearance. 43 
44 
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Introduction 45 
Failure of lamellar energy metabolism may be an important contributor to laminitis 46 
development (Belknap et al., 2009; French and Pollitt, 2004; Pass et al., 1998; van Eps et al., 47 
2010). In vitro lamellar glucose starvation causes hemidesmosome loss with resultant 48 
weakening of the dermo-epidermal connection and lamellar separation (French and Pollitt, 49 
2004; Pass et al., 1998). Despite the potential importance of bioenergetic disturbances in the 50 
pathogenesis of laminitis, very little is known about normal lamellar energy metabolism. 51 
 52 
Tissue microdialysis is a minimally invasive technique used to assess local energy 53 
metabolism through measurement of energy metabolites such as glucose, pyruvate and 54 
lactate. A probe with a semi-permeable membrane, introduced into the tissue of interest, is 55 
slowly and continuously perfused allowing molecules to diffuse across the membrane down 56 
their concentration gradient (de Lange, 2013). Therefore, metabolite concentrations in the 57 
microdialysis sample (dialysate) are reflective of the metabolite concentration in the 58 
interstitial fluid of the studied tissue (Klaus et al., 2004). Microdialysis is used in clinical and 59 
research settings to study tissue bioenergetic disturbances (ischaemic and non-ischaemic) 60 
particularly in the brain (Benveniste et al., 1989; Hillered et al., 2006; Klaus et al., 2004; 61 
Oddo et al., 2012a,b; Schulz et al., 2000). The addition of a known (high) concentration of 62 
urea to the perfusate allows for determination of urea clearance, an estimate of local 63 
perfusion (Farnebo et al., 2010).  64 
 65 
In horses, microdialysis has been used in pharmacokinetic studies and for assessment of 66 
muscle energy metabolism (Chou et al., 2001; Edner et al., 2005, 2009; Ingvastlarsson et al., 67 
1992; Murchie et al., 2006; Vickroy et al., 2008). Lamellar microdialysis has been described 68 
for pharmacokinetic studies (Nourian et al., 2010a, b). However, the previously reported 69 
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technique necessitated removal of a 2 cm diameter portion of hoof wall over the insertion 70 
site, potentially introducing heat artefact and interfering with normal mechanical forces 71 
acting on the sampled area. 72 
 73 
The primary objectives of the current study were: (1) to develop and evaluate a lamellar 74 
microdialysis technique without hoof wall disruption at the probe membrane site, and (2) to 75 
measure and compare energy metabolites in microdialysate from the lamellar, sublamellar 76 
and skin dermis of normal horses over 24 h. 77 
 78 
Materials and methods 79 
Animals and experimental design 80 
Fourteen clinically normal Standardbred horses (12 geldings and 2 mares; mean age, 6.5 81 
± 3.03 years; mean bodyweight, 461.2 ± 49.3 kg) with radiographically normal forefeet were 82 
used. The project was approved by the University of Queensland Animal Ethics Committee 83 
(approval number: SVS/257/11/GJRF) that monitors compliance with the Animal Welfare 84 
Act (2001) and The Code of Practice for the care and use of animals for scientific purposes 85 
(current edition). 86 
 87 
Three experiments were performed. In experiment 1, linear microdialysis probes were 88 
inserted in the lamellar dermis (LAM) of one forelimb (Figs. 1A and B) and the skin dermis 89 
(SKIN) over the tail base in six horses. Simultaneous samples were obtained every 2 h for 90 
comparison of metabolites over a 24 h period with horses confined to stocks. Four of these 91 
horses then had the probes removed and were monitored for 1 month afterwards to assess 92 
recovery. In experiment 2, dialysate metabolite concentrations in the sublamellar dermis and 93 
lamellar dermis were compared by inserting two coaxial microdialysis probes into each 94 
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forelimb of two horses: one directed into the sublamellar dermis (SUBLAM) and the other 95 
into the LAM (Figs. 1C and D). Simultaneous hourly sampling was performed for 4h in 96 
stocks. Experiment 3 was performed to further assess dialysate metabolite concentrations in 97 
the SUBLAM: coaxial microdialysis probes were placed in the SUBLAM of one foot (Fig. 98 
1C) in six horses and sampling was performed every 2 h for 24 h with horses confined to 99 
stocks. In two of these horses, sampling was continued every 6 h for an additional 96 h in a 100 
stall. 101 
 102 
Microdialysis probe placement and perfusion 103 
For lamellar (LAM and SUBLAM) placement, keratinized tissue was resected from the 104 
white line region (on midline, dorsal to the point of the frog) with an electric rotating burr 105 
(Die-Grinder, Makita) to create an ovoid 1.5 × 1.0 cm hole, leaving the majority of the 106 
stratum medium of the distal hoof wall intact. The depth was slowly increased until the white 107 
line was easily depressed with forceps. Bilateral abaxial sesamoid perineural anaesthesia was 108 
performed with 2% lignocaine (Ilium Lignocaine 20, Troy Laboratories).  109 
 110 
After aseptic preparation of the hoof and pastern, the hoof was covered with a sterile 111 
adhesive drape (Ioban, 3M). Spinal needles (15 cm) were used as introducers for lamellar 112 
probe placement. A 20 G needle (Becton-Dickinson) was used for linear probes (CMA66, 113 
CMA-Microdialysis) and an 18 G needle (Lochimed) for coaxial probes (CMA20, CMA-114 
Microdialysis). The needles were inserted at the white line and advanced proximally (parallel 115 
with the dorsal hoof wall for LAM placement and at a ~5º angle toward the third phalanx for 116 
SUBLAM placement) until the tip appeared through the skin above the coronet. The stylet 117 
was removed and a microdialysis probe with a 10 × 0.5 mm, 100 kDa cut-off membrane was 118 
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inserted to position the probe membrane in the mid lamellar region. The needle was removed 119 
leaving the probe in place (Figs. 1A and C).  120 
 121 
The inlet/outlet tubing was passed through a 2 mm hole drilled in the distal hoof wall 122 
defect to emerge on the dorsal surface of the hoof. The outlet tubing was connected to a 123 
custom made microdialysis vial holder (Fig. 1B) secured to the dorsal hoof wall, and the inlet 124 
tubing was connected to a precision pump (CMA107, CMA-Microdialysis) housed in a 125 
custom limb boot over the metacarpus. The defect at the toe was filled with silicone putty 126 
(Hoof-Life).  127 
 128 
For SKIN probe placement, a linear microdialysis probe with a 10 × 0.26 mm, 55 kDa 129 
cut-off membrane (CMA31, CMA-Microdialysis) was inserted into the dermis over the tail 130 
base using a 21 G, 38 mm needle (Becton-Dickinson), after aseptic preparation and 131 
subcutaneous infiltration with local anaesthetic (2% lignocaine). The inlet tubing was 132 
connected to a precision pump (CMA107) and the outlet tubing to a microdialysis vial 133 
(Microvial, CMA-Microdialysis), both secured to the tail. 134 
 135 
All probes were perfused with an isotonic, polyionic sterile perfusion fluid (T1, CMA-136 
Microdialysis) containing 40 g/L dextran-70 (Sigma-Aldrich) to prevent perfusate loss 137 
(Rosdahl et al., 1997). The perfusate in experiments 2 and 3 contained urea (20 mmol/L) for 138 
determination of urea clearance (Farnebo et al., 2010). All probes were perfused for 30 min 139 
prior to implantation, then continuously at a rate of 1 µL/min throughout the experiments. 140 
The perfusion rate was decreased to 0.3 µL/min during the additional 96 h sampling period in 141 
stalls for two horses in experiment 3. 142 
 143 
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Sample collection and analysis 144 
After probe insertion, a 2 h stabilization period was allowed before commencement of 145 
sample collection. Dialysate samples were simultaneously collected every 2 h from the LAM 146 
and SKIN probes (experiment 1), hourly from SUBLAM and LAM probes (experiment 2) 147 
and every 2 h from SUBLAM probes in experiment 3. The collected dialysate samples were 148 
weighed and fluid recovery calculated as a percentage of the perfused volume during the 149 
sampling period (120 µL). Glucose, lactate, pyruvate, urea and glycerol concentrations were 150 
determined immediately (analysed within 3 min of sample collection) using a commercially 151 
available, dedicated microdialysis analyser (IscusFlex, CMA-Microdialysis). Standard 152 
indices of energy metabolism (lactate:glucose [L:G] and lactate:pyruvate [L:P]) were 153 
calculated. 154 
 155 
Lameness evaluation 156 
Digital pedometers (Digiwalker sw700, Yamax) were taped to the distal antebrachium 157 
of both forelimbs in all horses to record weight shifting frequency across the entire sampling 158 
period (counts recorded and reset every 2 h). Lameness evaluations were performed 159 
immediately prior to and at the conclusion of the entire sampling period in each experiment. 160 
Each horse was walked and trotted towards and away from the observer and circled to the 161 
right and left. Lameness was graded on a 0 – 5 scale following the AAEP guidelines1. In the 162 
four horses from experiment 1 where the probes were removed, lameness evaluations and 163 
visual inspection of the hooves were performed weekly for 4 weeks.  164 
 165 
Histology 166 
                                                 
1 American Association of Equine Practitioners; see: www.aaep.org 
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Two horses from experiment 1, and all horses in experiments 2 (n = 2) and 3 (n = 6) 167 
were euthanased with pentobarbital sodium (20 mg/kg IV) (Lethabarb, Virbac) and lamellar 168 
tissue harvested and prepared for light microscopy as previously described (Pollitt, 1996). 169 
The area of skin containing the SKIN probe was also harvested. The tissue sections were 170 
blindly assessed by a specialist veterinary pathologist (REA) and scored using a semi-171 
quantitative method (Table 1). 172 
 173 
Statistical analysis 174 
The data failed normality testing therefore non-parametric tests were used. The 175 
concentrations of dialysate analytes, ratios (L:G and L:P), fluid recovery, and pedometer 176 
counts  were   compared   over   time  using  Friedman   analysis  with  Dunn’s   post-tests, and also 177 
between LAM and SKIN at each time point in experiment 1 using Wilcoxon signed-rank 178 
tests. The median concentrations of analytes and calculated ratios were compared between 179 
LAM and SKIN (experiment 1), and SUBLAM (experiment 3) using Mann-Whitney tests. 180 
Wilcoxon signed-rank tests were also used to compare pedometer count frequencies between 181 
limbs (experiments 1 and 3). Data from experiment 2 were analysed descriptively. Statistics 182 
were performed using GraphPad Prism v6.00 for Windows (GraphPad Software) with 183 
significance set at P < 0.05. Data are expressed as median with interquartile range (IQR).  184 
 185 
Results 186 
Probe performance and clinical effects 187 
In each horse the microdialysis probes remained in position and were functional 188 
throughout the 24-h study periods whilst confined to stocks. Pedometer count frequency did 189 
not differ significantly between limbs and was not significantly different over time in any 190 
experiment (data not shown). The lameness score was 0 at each observation interval for all 191 
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horses, including over the 1-month follow-up period (n = 4; experiment 1) and there were no 192 
visible changes in external hoof wall and sole morphology during this period. 193 
 194 
Dialysate analysis 195 
Fluid recovery did not vary significantly over time (Fig. 2), nor was there a difference 196 
between LAM (100.1%, [97.0-102.4%]), SKIN (95.7%, [90.7-99.3%]) and SUBLAM 197 
(101.7%, [99.6-103.9%]) recovery. When considering the median dialysate analyte values 198 
from all time-points during experiments 1 and 3 (Table 2), LAM glucose concentrations were 199 
lower and LAM L:G higher than both SKIN and SUBLAM, LAM endogenous urea 200 
concentrations were lower than SKIN, and SUBLAM pyruvate concentrations were higher 201 
than SKIN (P < 0.05). SUBLAM and LAM urea concentrations were not compared due to 202 
the addition of urea to the dialysate for urea clearance studies in experiment 3. In all three 203 
experiments, median concentrations of glucose, lactate, pyruvate and urea, as well as L:G and 204 
L:P did not differ significantly over time in LAM, SKIN and SUBLAM dialysate, whereas 205 
glycerol concentration decreased significantly (P < 0.05) in each (Fig. 2).  206 
 207 
In experiment 2, glucose and pyruvate concentrations appeared to be lower, and L:G 208 
higher in LAM vs. SUBLAM dialysate; however the data were not statistically analysed (Fig. 209 
3). Urea (mmol/L) also appeared to be higher in LAM (13.53, [13.2-13.6]) vs. SUBLAM 210 
(11.18, [10.11–12.03]). The perfusate urea concentration was not measured in experiment 2. 211 
The urea concentration (mmol/L) in SUBLAM dialysate in experiment 3 was 14.83 [13.95-212 
14.92] with a measured perfusate concentration of 17.92 [17.54-18.36]. 213 
 214 
Extended sampling (96 h in stalls) in two horses (H5 and H6) from experiment 3 yielded 215 
an overall fluid recovery of 98.84% [91.32-100.8]; however breakage of the vial holders (H5: 216 
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18 h and H6: 60 h) and disruption of tubing connections (H5: 36 h and H6: 12 h; 24 h) 217 
occurred. Metabolite concentrations were similar to the initial 24-h period in stocks and 218 
appeared stable until time point 48 h (H5) and 66 h (H6), after which a rapid decrease in 219 
glucose and increase in lactate concentrations was observed (data not shown). Glucose 220 
concentrations (mmol/L) were 0.06 (H5) and 0.0 (H6) at the last sampling time point. Other 221 
metabolite values remained stable. 222 
 223 
Probe location and host reaction 224 
 Histological examination confirmed that probe membrane placement was in the desired 225 
LAM, SKIN and SUBLAM position in all tissue sections (Fig. 4). With LAM placement, 226 
damage to adjacent primary epidermal lamellae (PEL) was observed (Fig. 4A), whereas no 227 
evidence of damage to PEL was apparent with SUBLAM probes (Fig.4B). There was 228 
evidence of mild to moderate inflammation and cellular debris, mild endothelial reactivity, 229 
oedema and haemorrhage around each probe. Neutrophils were the predominant cell type 230 
with rare macrophages and lymphocytes. The histological scores for each location are 231 
presented in Table 3. Overall, the host response to microdialysis probe implantation was 232 
mild, regardless of probe location, and consistent with tissue damage due to probe placement 233 
and wound healing responses relative to the time the probe was in situ (24 h vs. 120 h). 234 
 235 
Discussion 236 
Lamellar microdialysis allowed for consistent recovery of dialysate samples and was well 237 
tolerated. Fluid recovery from LAM, SUBLAM and SKIN probes was similar and consistent 238 
throughout the study. The minor disruption of the distal hoof wall and sole that was required 239 
for probe insertion was remote from the sampling site (microdialysis membrane). 240 
Maintaining tissue integrity around the membrane is likely to be important when studying the 241 
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effects of weight bearing and limb load cycling on lamellar perfusion and bioenergetics, as 242 
mechanical forces operating on the soft tissue between hoof wall and distal phalanx may 243 
affect perfusion (Redden, 2003; van Eps et al., 2010).  244 
 245 
Metabolite concentrations were stable for 24 h and there was minimal histological 246 
response to the probes, suggesting that analyte recovery was unlikely to be affected by 247 
fibrous capsule formation or host response to the probe. These findings suggest that 248 
microdialysis is suitable for evaluating disturbances in lamellar energy metabolism over time, 249 
particularly during laminitis development; however, it should be noted that sampling in the 250 
current study was confined to a single region (dorsal lamellae), which may not be 251 
representative of lamellar tissue in other regions of the foot.  Sampling in two horses moving 252 
freely in a stall for 96 h was achieved, but a decrease in glucose followed breakage of the 253 
microdialysis system in both horses. The decrease was likely due to bacterial contamination 254 
of the microdialysis system itself (a recognised cause of low glucose concentration artefact) 255 
(Heller and Feldman, 2013), since there was minimal histological evidence of a foreign body 256 
reaction (the other major cause of low glucose artefact in microdialysis) (Nichols et al., 257 
2011). A more robust collection system is required for ambulatory studies and studies of 258 
longer duration.  259 
 260 
The lower glucose and endogenous urea concentrations in LAM compared with SKIN 261 
may be due to the presence of lower blood flow in lamellar tissue, increased glucose uptake 262 
by surrounding cells, or a combination of both. Interstitial glucose concentrations may also be 263 
influenced by blood glucose concentration, but this would be expected to equally affect 264 
simultaneous LAM and SKIN samples. Both glucose and urea must be delivered to the 265 
lamellae and skin haematogenously (Hall, 2011; Sorg et al., 2005), but only glucose is 266 
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consumed. Therefore, the lower LAM endogenous urea concentration compared with SKIN 267 
supports the existence of comparatively lower perfusion in the lamellar dermis. The lower 268 
LAM glucose concentration compared to SUBLAM and SKIN supports the existence of 269 
higher glucose consumption at the site of LAM probe placement (between avascular, but 270 
glucose-consuming epidermal lamellae). A high rate of glucose consumption has been 271 
demonstrated in the equine digit and this probably reflects the rate of glycolysis, since there is 272 
no local means of glycogen storage in lamellar tissue (Wattle and Pollitt, 2004). 273 
 274 
Lamellar perfusion was assessed further in experiments 2 and 3 using urea clearance 275 
(Farnebo et al., 2010). In experiment 3 (SUBLAM), urea concentrations remained stable over 276 
time, indicating the method may be useful for documenting changes in perfusion over time. 277 
In experiment 2 there appeared to be lower urea concentrations (higher urea clearance) in 278 
SUBLAM compared to simultaneous LAM samples, which may suggest lower local 279 
perfusion in the LAM region. Urea clearance was not used in experiment 1 because an 280 
objective was to determine the endogenous dialysate concentrations of all analytes (including 281 
urea). Further evaluation of the urea clearance technique is required to determine whether 282 
changes in lamellar perfusion can be detected. 283 
 284 
Increased dialysate L:G has been observed with hypoxia and ischaemia in brain tissue, 285 
where it is the consequence of a combination of increased extracellular lactate and reduced 286 
glucose (Goodman et al., 1999; Meierhans et al., 2010). The high LAM L:G in this study was 287 
due to the significantly lower LAM dialysate glucose concentrations (rather than higher 288 
lactate concentrations), since LAM dialysate lactate concentrations were similar to those of 289 
the SKIN, SUBLAM and previously reported tissues such as brain (Langemann et al., 2001) 290 
and muscle (Edner et al., 2005). Therefore, the high L:G in normal LAM (more than twice 291 
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that of SKIN, SUBLAM and other previously studied tissues) suggests the presence of a high 292 
glycolytic rate in the lamellae (glucose consumption with production of lactate), which is 293 
typical of epidermal tissues (Ronquist et al., 2003; Wattle and Pollitt, 2004). The lack of 294 
lactate accumulation suggests that lamellar tissue is adapted to the high rate of glycolysis, 295 
with the lactate produced being either utilised as an energy source via lactate dehydrogenase 296 
(LDH; richly present in lamellar epidermis) (Wattle and Pollitt, 2004) or removed efficiently 297 
via a lactate shuttle (Gladden, 2004).  298 
 299 
Other metabolite values (lactate, pyruvate, glycerol) were similar in all sampled tissues 300 
and also similar to values reported for the healthy human brain under similar microdialysis 301 
conditions (Reinstrup et al., 2000). In the current study, the perfusion rate of 1 µL/min was 302 
chosen as it allows for collection of adequate volumes of dialysate over short sampling 303 
intervals   (≤15   min),   a   requirement   for   ongoing   studies   in   the   authors’   laboratory.   This  304 
relatively high flow rate reduces metabolite recovery (Benveniste and Huttemeier, 1990); 305 
therefore measured dialysate metabolite concentrations were assumed to be much lower than 306 
the absolute values in the interstitial fluid. The pattern of initially high glycerol 307 
concentrations, decreasing over 24 h in the current study was also observed in equine muscle 308 
(Edner et al., 2005), and is likely the result of cell membrane damage caused by probe 309 
insertion. Measurement of other markers of cell membrane damage such as LDH (Glick, 310 
1969) is also possible in microdialysis fluid and should be considered in future studies.  311 
 312 
The L:P measured at all sites in the current study resembled values previously reported 313 
for brain (Zhang and Natowicz, 2013) and muscle (Edner et al., 2005). The L:P is indicative 314 
of tissue redox status (which is dependent on mitochondrial function and tissue oxygenation), 315 
and an increase in L:P is the most reliable indicator of energy metabolism dysfunction 316 
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(ischaemic and non-ischaemic) in well studied tissues (Hillered et al., 2006; Setala et al., 317 
2004; Waelgaard et al., 2012). In fact L:P is considered a sensitive marker of cellular 318 
metabolic dysfunction (Vespa et al., 2005) and is used in the diagnostic evaluation of 319 
disorders of energy metabolism in a range of tissues (Marcoux et al., 2008; Zhang and 320 
Natowicz, 2013). Therefore, lamellar dialysate L:P may be useful for detecting the presence 321 
of bioenergetic failure during the development of different forms of equine laminitis. The L:P 322 
in lamellar dialysate in the present study was similar to that of SKIN and also brain and 323 
muscle in previous studies, suggesting a similar resting redox state. This appears to be at odds 324 
with the findings of Pawlak et al. (2014), who concluded that the equine epidermal lamellar 325 
tissue is comparatively hypoxic.  326 
 327 
In the current study, the contribution of epidermal cell metabolism (basal cells and deeper 328 
epidermal cell layers) to the dialysate composition is not clear since the probes were placed in 329 
the dermis (either between PEL (LAM) or adjacent to the PEL tips (SUBLAM)). The 330 
sampling area of a microdialysis probe may depend on the tissue and the analyte. However, it 331 
has been estimated to be 50 times the membrane thickness (Benveniste et al., 1989) or 332 
calculated by mathematical models to be 0.85 ± 0.25 mm for neuroactive substances in the 333 
brain (Diczfalusy et al., 2011), suggesting that in the present study, both epidermal and 334 
dermal lamellar tissues should have influenced the dialysate regardless of probe position. 335 
However, immediately adjacent tissues are likely to have more influence on dialysate 336 
composition, which may account for the differences observed between LAM and SUBLAM. 337 
 338 
The limitations of the present study include the use of different microdialysis probes and 339 
the lack of ambulation (having the horses restrained in stocks). Membrane characteristics 340 
were however similar for all probes, with CMA20 and CMA66 probes having identical 341 
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membrane characteristics, and the CMA31 differing only in pore size (55 kDa). Net transport 342 
of metabolites across the microdialysis membrane (recovery) depends mainly on perfusate 343 
flow rate, membrane size (area) and how diffusible each metabolite is in the sampled tissue 344 
(Hamrin et al., 2002; Rosdahl et al., 1998). Therefore, the difference in membrane pore sizes 345 
is likely negligible, particularly considering the molecular weight of the largest metabolite 346 
measured in the present study (glucose) was 0.18 kDa. Although it is possible that the 347 
lamellar bioenergetic profile in stationary horses differs from that of ambulating horses, 348 
restraining the study subjects in stocks was necessary for frequent sampling and protection of 349 
the equipment. Sampling was only performed in two freely moving horses to assess if long-350 
term lamellar microdialysis was achievable, and a different perfusion rate was used for 351 
convenience (6-h sampling interval), preventing comparisons between ambulating and 352 
standing static horses from being performed.  353 
 354 
This study is the first to evaluate with histology the tissue response to microdialysis probe 355 
placement in horses. The scoring system was designed to represent the range of pathology 356 
present in the samples scored, rather than to act as a comparison with other foreign body 357 
responses. Overall the histological changes were benign and not suggestive of a foreign body 358 
response driven by the microdialysis membrane. 359 
 360 
Conclusions 361 
Tissue microdialysis is a suitable method for energy metabolite sampling in the equine 362 
lamellar and skin dermis. Recovery of dialysate was consistent and the concentrations of 363 
measured metabolites were stable for 24 h. There were no adverse clinical effects of probe 364 
implantation and histological reactions were mild. In the standing, static horse, the lamellar 365 
dialysate had lower glucose and urea concentrations and a higher L:G compared to skin 366 
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(consistent with lower perfusion and/or higher glucose consumption), but lamellar L:P, the 367 
most useful marker of energy homeostasis, was similar to skin and previously studied tissues. 368 
Probe position (lamellar vs. sublamellar dermis) affected microdialysate metabolite 369 
concentrations, which is likely to be a factor of proximity to the avascular, but metabolically 370 
active epidermis. 371 
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Table 1: Semi-quantitative histological scoring system applied to the lamellar and skin 554 
dermis tissue slides. The scoring system was designed to represent the range of 555 
pathology present in the samples scored and is not a comparison to other foreign body 556 
responses. HPF, high power field. 557 
 558 
Score 0 1 2 3 
Epidermal basal cell and parabasal cell 
hyperplasia (fold increase in thickness of 
epidermal cell layer) 
Absent 2 fold 3 fold ≥  3  fold 
Flattening of secondary epidermal 
lamellae (SEL): expressed as % of length of 
unaffected SEL remaining 
100% 66-99% 50-66% <50% 
Mitotic figures: per HPF (200X) 0 1 2 ≥3 
Inflammatory cell count around the probe 
per HPF at 200X 0 1-50 50-100 >100 
Oedema Absent Mild Moderate Marked 
Haemorrhage Absent Mild Moderate Marked 
Fibroplasia: thickness of the fibrous tissue 
around the probe  
Absent Mild Moderate Marked 
Collagen bundle formation Absent Mild Moderate Marked 
Cellular debris  Absent Mild Moderate Marked 
Endothelial reactivity: number of vessels 
with reactive endothelium per HPF (200X) 0 1-20 21-50 >50 
Tissue necrosis Absent Mild Moderate Marked 
 559 
560 
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Table 2: Median and interquartile range (IQR) concentrations of energy metabolites, urea, 561 
glycerol and standard calculated ratios in lamellar dermis (LAM) and skin dermis (SKIN) 562 
dialysate in experiment 1, and sublamellar dermis (SUBLAM) dialysate in experiment 3 for 563 
the entire 24 h sampling period.  564 
 LAM SKIN SUBLAM 
Glucose 
(mmol/L) 
0.45 1,2 
(0.38-0.50) 
1.23 1 
(1.08-1.39) 
0.83 2 
(0.73-1.13) 
Lactate 
(mmol/L) 
1.32 
(1.09-1.52) 
1.45 
(1.34-1.50) 
1.22 
(1.11-1.31) 
Pyruvate 
(µmol/L) 
65.45 
(50.90-76.64) 
72.10 3 
(69.35-74.88) 
54.04 3 
(43.51-59.65) 
Glycerol 
(µmol/L) 
5.04 
(3.79-8.05) 
3.10 
(2.37-4.38)  
7.38 
(4.61-12.06) 
Urea 
(mmol/L) 
2.63 1 
(2.30-2.81)  
3.72 1  
(3.55-4.06) 
14.83 4 
(13.95-14.92) 
Lactate:Glucose 2.84 
1,2 
(2.64-3.63) 
1.21 1 
(1.04-1.34) 
1.44 2 
(1.12-1.77) 
Lactate:Pyruvate 20.33 (18.07-22.82) 
21.34 
(19.36-23.15)  
25.57 
(23.41-28.59) 
  565 
1 Statistically significant (P < 0.05) difference between LAM and SKIN. 2 Statistically 566 
significant (P < 0.05) difference between LAM and SUBLAM. 3 Statistically significant (P < 567 
0.05) difference between SKIN and SUBLAM. 4 Perfusate contained 20 mmol/L of urea. 568 
569 
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Table 3: Median and interquartile range (IQR) histological score in the tissue surrounding 570 
the probe for LAM, SKIN, SUBLAM, and for different implantation duration (24 h vs. 120 571 
h).  Medians  are  ≤  1  for  all  subcolumns  except  after  120  h  in  situ,  indicative  of  a  mild  host  572 
response to microdialysis probe implantation. The scoring system represents the range of 573 
pathology present in the samples scored. The histological changes were not suggestive of a 574 
foreign body response driven by the microdialysis membrane. EBC, epidermal cell 575 
hyperplasia; SEL, secondary epidermal lamellae; PMN, polymorphonuclear neutrophils. 576 
 577 
Parameter Experiment 1 Experiment 2 Experiment 3 LAM SKIN LAM SUBLAM 24 h 120 h 
EBC hyperplasia  0 (0-0) N/A 
0 
(0-0) 
0 
(0-0) 
0 
(0-0) 
1.5 
(0-3) 
Flattening of SEL 0 (0-0) N/A 
0 
(0-0) 
0 
(0-0) 
0 
(0-0) 
1.5 
(0-3) 
Mitotic figures 0.5 (0-1) 
0 
(0-0) 
0 
(0-0) 
0 
(0-0) 
0 
(0-0) 
0 
(0-0) 
Inflammatory cell count 1 (1-1) 
1.5 
(1-2) 
3 
(1.5-3) 
2 
(2-2.75) 
1.5 
(1-2.75) 
3 
(3-3) 
- cell type PMN PMN PMN PMN PMN PMN 
Oedema 2 (2-2) 
1 
(1-1) 
1 
(1-2.5) 
1 
(1-2.5) 
1.5 
(0.25-2) 
0.5 
(0-1) 
Haemorrhage 1 (1-1) 
1 
(1-1) 
1 
(1-1) 
1.5 
(1.25-2) 
1.5 
(0.25-2.75) 
0.5 
(0-1) 
Fibroplasia 0 (0-0) 
0 
(0-0) 
0 
(0-0) 
0 
(0-0) 
0 
(0-0) 
2 
(2-2) 
Collagen bundles 0 (0-0) 
0 
(0-0) 
0 
(0-0) 
0 
(0-0) 
0 
(0-0) 
1 
(1-1) 
Cell debris 2 (2-2) 
1.5 
(1-2) 
2.5 
(1.25-3) 
1.5 
(1-2.75) 
2 
(0.5-2.75) 
3 
(3-3) 
Endothelial reactivity 1.5 (1-2) 
1 
(1-1) 
1 
(0.25-2.5) 
2 
(1-3) 
0.5 
(0-2.5) 
2 
(1-3) 
Tissue necrosis 1.25 (0.5-2) 
0 
(0-0) 
0.5 
(0.5-0.86) 
1.5 
(0.62-2.75) 
1 
(1-1.75) 
1.5 
(1-2) 
Total median (IQR) 1 (0-1.5) 
1 
(0-1.25) 
0.5 
(0-1) 
1 
(0-1.5) 
0.5 
(0-1.5) 
1.5 
(0.5-2) 
 578 
 579 
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Figure legends 580 
 581 
Fig. 1. Schematic representation of the tissue microdialysis linear probe system used in 582 
experiment 1 (A): the microdialysis membrane is located within the mid-dorsal lamellar 583 
tissue, the outlet tubing is connected to a collection vial within a custom-made vial holder on 584 
the dorsal hoof wall (B). Schematic representation of a tissue microdialysis coaxial probe 585 
system used in experiments 2 and 3 (C): the microdialysis membrane is located within the 586 
mid-dorsal lamellar tissue: the inlet and outlet tubing emerge through the white line and via a 587 
hole in the hoof wall are connected to a microdialysis pump and a collection vial on the 588 
dorsal hoof wall, respectively. For Experiment 2, two tissue microdialysis coaxial probes 589 
were placed 1 cm lateral and medial of midline for simultaneous comparison of dialysate 590 
from LAM (probe introducer inserted parallel to hoof wall) and SUBLAM (probe introducer 591 
inserted at a ~5º angle towards the third phalanx) (D). The dotted lines depict the internal 592 
location of the probes. 593 
 594 
Fig. 2. Median ± interquartile range (IQR) concentrations of energy metabolites, urea, 595 
glycerol, L:G, L:P and dialysate recovery in LAM, SKIN (experiment 1), and SUBLAM 596 
(experiment 3) vs. time. Glycerol was the only analyte that varied significantly over time, 597 
decreasing compared to baseline (2 h) in the dialysate from each tissue. The concentrations of 598 
glucose, and urea were significantly lower in LAM compared to SKIN (P<0.05). The L:G 599 
was significantly higher in LAM compared SKIN (P < 0.05). Fluid recovery is expressed as a 600 
percentage of the infused volume for each sampling interval (120 µL in 2 h). Fluid recovery 601 
did not vary significantly over time.  602 
1, significant difference (P < 0.05) between LAM and SKIN in experiment 1 at this time 603 
point; 2, significant difference (P < 0.05) vs. 2 h for LAM dialysate in experiment 1 at this 604 
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time point; 3, significant difference (P < 0.05) vs. 2 h for SKIN dialysate in experiment 1 at 605 
this time point; 4, significant difference (P < 0.05) vs. 2 h for SUBLAM dialysate in 606 
experiment 3 at this time point. 5, perfusate contained 20 mmol/L of urea. 607 
 608 
Fig. 3. Median and interquartile range (IQR) concentrations of energy metabolites, urea, 609 
glycerol and standard calculated ratios in simultaneous LAM and SUBLAM dialysate 610 
samples in four feet from two horses (experiment 2) over a 4-h period. A lower concentration 611 
of glucose and pyruvate, lower urea clearance, and a higher lactate:glucose (L:G) was 612 
apparent in LAM vs. SUBLAM dialysate (descriptive analysis only; n = 2). 613 
 614 
Fig. 4: Haematoxylin and eosin-stained light microscopy at 4x magnification showing the 615 
position of the microdialysis probe membranes (P) in representative sections from LAM (A); 616 
SUBLAM (B); and SKIN (C). There was damage to primary epidermal lamellae (white 617 
asterisks) neighbouring the probe in all of the LAM sections, but not in SUBLAM sections. 618 
White arrow heads, skin hair follicles. 619 
 620 
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